

Rerouting Minds

It's time to shift our perceptions of pharmaceutical LSD and explore its potential to support positive mental pathways and forge enduring outcomes.

The Need for Innovation in Mental Health Treatment



1 in 4 adults in the U.S. live with a mental health disorder.¹



Only 1/3 of patients with major depressive disorder experience remission from first-line therapy.²



It has been over 18 years since a new treatment was approved for generalized anxiety disorder.³



Challenges of existing treatments include dosing burdens, slow onset of effect, poor tolerability, and difficulty with adherence, contributing to discontinuations, patient frustration and persistent disease burden.^{4,5}



A Full Circle Moment for LSD

A growing body of promising evidence from well-controlled, scientifically rigorous clinical studies has emerged, exploring the potential of LSD and other psychedelics to shape how mental health disorders are treated.⁶

Certain psychedelics, such as LSD, are believed to catalyze periods of neuroplasticity, the brain's remarkable capacity to rewire itself on a microscopic scale. It is thought that LSD's dual mechanism—the molecule's 5-HT_{2A} receptor binding and the resultant experience of the patient and the downstream activation of neurobiological pathways—together enhance clinical effects, potentially accounting for reductions in anxiety that are rapid and lasting without the burden of side effects associated with the current standard of care.

The History of LSD Research



For more resources and to learn more about rerouting minds visit: <https://www.definiumtx.com/rerouting-minds/>



The Definium Difference: Scientific Rigor, Regulatory Framework, Robust Collaboration

Definium Therapeutics is forging a new era of psychiatry by advancing controlled clinical trials that will help explore efficacy and safety while ensuring physicians and public health professionals understand the potential role of pharmaceutical LSD in the therapeutic setting.

References:

1. Mental Illness. National Institute of Mental Health. <https://www.nimh.nih.gov/health/statistics/mental-illness>. Accessed November 2025.
2. Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D Report. *Am J Psychiatry*.
3. FDA approves Cymbalta for treatment of generalized anxiety disorder. News release. Lilly; February 26, 2007. Accessed November 2025. <https://investor.lilly.com/static-files/499f0aa3-281f-49f4-9655-049aae179593>.
4. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. *Ann Intern Med*. 2011;155(11):772-785.
5. Machado-Vieira R, Baumann J, Wheeler-Castillo C, et al. The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. *Pharmaceuticals (Basel)*. 2010;3(1):19-41.
6. Kurtz JS, et al. The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry. *Cureus*. 2022;14(9):e29167.
7. LSD Toxicity. Medscape. <https://emedicine.medscape.com/article/1011615-overview>. Accessed November 2025.
8. Baquiran M, Keyes D, Al Khalili Y. Lysergic Acid Diethylamide Toxicity. [Updated 2023 Dec 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. <https://www.ncbi.nlm.nih.gov/sites/books/NBK553216/>. Accessed November 2025.